Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
VanEck Pharmaceutical ETF(PPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PPH
10/28/2026: PPH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
The VanEck Pharmaceutical ETF (PPH) provides targeted, market-cap-weighted exposure to the U.S. pharmaceutical industry. It is a well-established, liquid option for investors seeking a pure-play approach to drug manufacturers without the noise of broader healthcare components. Its main strengths include a focused investment thesis and reliance on major, stable industry leaders, making it a reliable satellite holding for income and defensive portfolio tilts. However, investors must monitor regulatory risks regarding drug pricing and the inherent concentration risk of holding a limited basket of companies. It is most suitable for long-term investors comfortable with sector-specific volatility and those seeking exposure to the steady cash flows of major pharmaceutical firms.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Pharmaceutical companies often focus on long-term R&D cycles rather than aggressive, rapid short-term growth. |
| Momentum investor | Strong fit while signal remains positive | The sector can exhibit strong momentum when positive clinical trial results or regulatory approvals occur. |
| Value investor | Strong fit | Many large-cap pharmaceutical firms offer stable dividends and lower P/E ratios compared to the broader technology sector. |
| Dividend/Income investor | Strong fit | Established pharmaceutical companies are frequently known for consistent, reliable dividend payments. |
| Low-risk investor | Mixed fit | While healthcare is defensive, sector-specific concentration introduces risks related to regulation and drug failure. |
Investor Profile
Ideal Investor Profile
The ideal investor is looking for specialized exposure to the pharmaceutical industry, likely as a satellite holding to diversify a core portfolio.
Suitability
Best for long-term investors seeking defensive stability and dividend potential, rather than short-term traders looking for rapid gains.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | Medium | Pharmaceutical stock prices can swing significantly based on FDA trial outcomes and litigation. |
| Market risk | Medium | The fund is subject to general equity market downturns, though it may provide some defensive characteristics. |
| Concentration | High | The fund holds a limited number of stocks, increasing the impact of a single company's poor performance. |
| Tracking/expense | Low | The fund maintains a low tracking error relative to its benchmark. |
| Liquidity | Low | Underlying holdings are generally large-cap and highly liquid. |
| Business/sector quality | Medium | Political pressure on drug pricing remains a significant long-term structural risk for the industry. |
Risk Analysis
Volatility
PPH exhibits moderate volatility, generally in line with the healthcare sector, as it is less sensitive than high-growth tech but more sensitive than consumer staples.
Market Risk
The primary risk is sector-specific; if the pharmaceutical industry experiences regulatory or patent-related headwinds, the fund's assets will decline regardless of the broader market's health.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Pharmaceuticals and Biotech Equities | 99.5 | This provides concentrated exposure to the largest and most established pharmaceutical companies in the U.S. market. |
| Cash/collateral | Cash and Cash Equivalents | 0.5 | Small cash position held for operational liquidity and trade settlement. |
Price Behavior
Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.
Very Smooth
The stock has followed a highly orderly price path with minimal short-term disruption.
Analysis of Past Performance
Type ETF | Historic Profit 30.92% | Avg. Invested days 67 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.